139 related articles for article (PubMed ID: 12425209)
1. [The significance of aldosterone in chronic heart failure: the RALES study].
Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
4. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone antagonists in congestive heart failure.
Soberman J; Chafin CC; Weber KT
Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
[TBL] [Abstract][Full Text] [Related]
6. [Anti-aldosterone therapy in severe heart failure].
van Guldener C; Donker AJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
[TBL] [Abstract][Full Text] [Related]
7. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
8. Induction of cardiac fibrosis by aldosterone.
Lijnen P; Petrov V
J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
[TBL] [Abstract][Full Text] [Related]
9. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
Cruz CS; Cruz LS; Domingues GS; Souza CA
Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
Shah NC; Pringle SD; Donnan PT; Struthers AD
J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
[TBL] [Abstract][Full Text] [Related]
13. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
Diercks GF; Overdiek JW; van Veldhuisen DJ
Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
[TBL] [Abstract][Full Text] [Related]
14. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Shah NC; Pringle S; Struthers A
J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
17. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Bansal S; Lindenfeld J; Schrier RW
Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
[TBL] [Abstract][Full Text] [Related]
18. [Classic treatment of chronic heart insufficiency. What if new?].
Aumont MC; Agnola D; Juliard JM; Karrillon G
Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):599-602. PubMed ID: 7487308
[TBL] [Abstract][Full Text] [Related]
19. [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
Alvarez JS; Vílchez FG
Rev Esp Cardiol; 2001 Feb; 54(2):175-80. PubMed ID: 11181306
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Pasquale PD; Stefano GD; Paterna S
Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
